Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · IEX Real-Time Price · USD
5.01
+0.01 (0.20%)
Mar 28, 2024, 4:00 PM EDT - Market closed
Aurinia Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for AUPH stock have an average target of 10.33, with a low estimate of 8.00 and a high estimate of 13. The average target predicts an increase of 106.19% from the current stock price of 5.01.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AUPH stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 3 | 3 | 3 | 3 | 2 | 2 |
Hold | 1 | 1 | 1 | 1 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 5 | 5 | 5 | 3 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +159.48% | Mar 1, 2024 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $12 → $10 | Buy | Maintains | $12 → $10 | +99.60% | Feb 23, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $13 | Strong Buy | Maintains | $15 → $13 | +159.48% | Feb 22, 2024 |
RBC Capital | RBC Capital | Buy Maintains $13 → $8 | Buy | Maintains | $13 → $8 | +59.68% | Feb 16, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +199.40% | Sep 22, 2023 |
Financial Forecast
Revenue This Year
228.73M
from 175.51M
Increased by 30.32%
Revenue Next Year
294.65M
from 228.73M
Increased by 28.82%
EPS This Year
-0.06
from -0.54
EPS Next Year
0.40
from -0.06
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 244.5M | 356.9M | 504.0M | 583.8M | 702.1M |
Avg | 228.7M | 294.7M | 378.3M | 487.7M | 538.2M |
Low | 202.9M | 245.0M | 288.1M | 279.3M | 318.5M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 39.3% | 56.0% | 71.0% | 54.3% | 44.0% |
Avg | 30.3% | 28.8% | 28.4% | 28.9% | 10.4% |
Low | 15.6% | 7.1% | -2.2% | -26.2% | -34.7% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 0.16 | 0.87 | 1.42 | 1.76 | 1.98 |
Avg | -0.06 | 0.40 | 1.16 | 1.17 | 1.29 |
Low | -0.33 | -0.14 | 0.78 | 0.39 | 0.64 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | 251.8% | 52.1% | 69.2% |
Avg | - | - | 187.8% | 1.2% | 10.0% |
Low | - | - | 94.6% | -66.2% | -45.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.